Clinical Trial Update: Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CHF5993 pMDI to Symbicort Turbuhaler in COPD completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF5993
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Status: COMPLETED